Drug updated on 12/11/2024
| Dosage Form | Injection (subcutaneous: 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL) |
| Drug Class | Somatostatin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy
- Indicated for the treatment of adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival
- Indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
Latest News
Summary
- This summary is based on the review of eight systematic review(s)/meta-analysis(es). [1-8]
- Maintenance and Achievement of Normal insulin-like growth factor (IGF)-I: Both lanreotide, octreotide, pegvisomant monotherapy, and pegvisomant combined with somatostatin receptor ligands (SRLs) observed normalization of IGF-I in ≥ 70% of patients across multiple studies.
- Disease Control by Administration Setting: Lanreotide and octreotide demonstrated similar disease control outcomes whether administered at home or in healthcare settings.
- Patient Preference and Extended Dosing Intervals (EDIs): Lanreotide was preferred in 4 out of 5 studies due to factors such as convenience and fewer injection-related issues; EDIs showed comparable clinical efficacy to standard regimens, with additional cost savings and higher patient satisfaction.
- Extended dosing intervals (EDIs) for lanreotide (LAN), octreotide (OCT), and pegvisomant showed similar safety profiles to standard regimens.
- Both LAN and OCT exhibited favorable safety profiles across various populations, including patients with multiple endocrine neoplasia type 1 (MEN1)-related pancreatic neuroendocrine neoplasms (pNENs) and type-1 gastric neuroendocrine tumors, though a high relapse rate (30.2%) was observed post-therapy discontinuation in type-1 gastric neuroendocrine tumors.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Somatuline depot (lanreotide) Prescribing Information. | 2024 | Ipsen Biopharmaceuticals, Inc., Cambridge, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. | 2023 | Cancer Treatment Reviews |
| A Pituitary Society update to acromegaly management guidelines | 2021 | Pituitary |
| Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | 2021 | Journal of National Comprehensive Cancer Network |
| JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis | 2021 | Journal of Gastroenterology |